Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)77 enrolled

Overview

The purpose of this first-in-human study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when administered as a single dose to healthy adult subjects by injection either in the muscle or under the skin.

A Phase 1, single-center, prospective, randomized, double-blind, single-dose and repeat single-dose, dose-escalation study to determine the safety, tolerability, and pharmacokinetics of CD388 Injection, as compared to saline placebo, when dosed either by intramuscular (IM) or subcutaneous (SQ) administration to healthy adult subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Healthy

Interventions

CD388 InjectionCOMBINATION_PRODUCT

CD388 liquid for injection

Saline placeboDRUG

Sterile normal saline for injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Males and females 18 to 65 years of age, inclusive. 3. A female subject must meet one of the following criteria: 1. If of childbearing potential - agrees to use a highly effective, preferably user-independent method of contraception (failure rate of \<1 percent per year when used consistently and correctly) for at least 30 days prior to screening and agrees to remain on a highly effective method until 205 days after last dose of study medication. Examples of highly-effective methods of contraception include: abstinence from heterosexual intercourse; hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch); intrauterine device (with or without hormones); or a double barrier method (e.g., condom and spermicide). 2. If a female of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by follicle-stimulating hormone (FSH) levels (≥40 milli-International units \[mIU\]/milliliter \[mL\]). 4. A woman of childbearing potential must have a negative highly sensitive serum pregnancy test (β-human chorionic gonadotropin) at screening and a negative urine pregnancy test on Day -1 before the first dose of study drug. 5. A male subject that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and until at least 205 days after the last dose of the study medication. 6. Good health and without signs or symptoms of current illness. 7. Normal clinical examination, including: 1. No physical examination findings that an Investigator determines would interfere with interpretation of study results. 2. Screening ECG without clinically significant abnormalities. 3. Creatinine clearance (CrCL) ≥80 mL/minute as calculated using the Cockcroft-Gault equation. 4. Negative urine screen for drugs of abuse and alcohol at screening and Day -1. 8. Body mass index (BMI; weight in kilograms \[kg\] divided by height in meters \[m\] squared) between 18.0 and 32.0 kg/m\^2, inclusive. 9. Willing to refrain from strenuous physical activity that could cause muscle aches or injury, including contact sports, at any time from screening through 30 days after any dose of study drug. 10. Subject has adequate venous access for blood collection. Exclusion Criteria: 1. History of any hypersensitivity or allergic reaction to zanamivir or other neuraminidase inhibitors (i.e., laninamivir, oseltamivir, peramivir), or to excipients of the CD388 Injection drug formulation; or history of drug-induced exfoliative skin disorders (e.g., Stevens-Johnson syndrome \[SJS\], erythema multiforme, or toxic epidermal necrolysis \[TEN\]). 2. History of any of the following: 1. Allergies, anaphylaxis, skin rashes (foods such as milk, eggs, medications, vaccines, polyethylene glycol \[PEG\], etc.). 2. Chronic immune-mediated disease, positive first-degree family history of autoimmune diseases. 3. Atopic dermatitis or psoriasis. 4. Bleeding disorder. 5. Psychiatric condition, seizures, hallucinations, anxiety, depression, or treatment for mental conditions. 6. Migraines. 7. Syncope, or vasovagal syndrome with injections or blood draws. 8. Cardiac arrhythmia. 3. Subjects with one or more of the following laboratory abnormalities at screening as defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1 (DAIDS 2017): 1. Serum creatinine, Grade ≥1 (≥1.1 × upper limit of normal \[ULN\]) 2. Pancreatic amylase or lipase, Grade ≥2 (≥1.5 × ULN) 3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT), Grade ≥1 (≥1.25 × ULN) 4. Total bilirubin, Grade ≥1 (≥1.1 × ULN) 5. Any other toxicity Grade ≥2, except for Grade 2 elevations of triglycerides, low density lipoprotein cholesterol, and/or total cholesterol. 6. Any other laboratory abnormality considered to be clinically significant by the Investigator. Note: Retesting of abnormal laboratory values that may lead to exclusion will be allowed once without prior asking approval from the Sponsor. Retesting will take place during a scheduled or unscheduled visit during screening. Subjects with a normal value at retest may be included. 4. Alcohol or drug addiction in the past 2 years. 5. Experiencing symptoms of acute illness or chronic disease within 14 days prior to check-in to the clinical research unit (CRU). 6. At screening, a positive result for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) antibody. 7. A positive result at screening or CRU check-in for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction (PCR). Beginning with Protocol Amendment 2, antigen testing may be used if PCR is not available. 8. Unwilling to comply with local health policy effective at the time regarding coronavirus disease 2019 (COVID-19).\* 9. Women who are pregnant or nursing. 10. Received any over-the-counter (OTC) medications or nutritional supplements within 7 days, or any prescription medications within 14 days or \<5 half-lives prior to dosing. 11. Current nicotine user or has quit habitual nicotine use in the 30 days prior to screening. 12. Received any vaccines or immunoglobulins within 28 days prior to dosing (90 days in case of intravenous immunoglobulin \[IVIg\] or biologics, or 14 days for COVID-19 vaccine).\*\* 13. Donated blood (within 56 days of screening) or plasma (within 7 days of screening) or experienced significant blood loss or significant blood draw when participating in non-interventional clinical trials within 60 days prior to dosing. 14. Received a blood transfusion within 28 days prior to dosing. 15. Received any biologics within 90 days prior to dosing. Previous participation in another study within 30 days or 5 half-lives of the study drug, whichever is longer, prior to screening; prior participation at any time in non-invasive methodology trials in which no drugs were given is acceptable. 16. The PI considers that the volunteer should not participate in the study. (\*) Full COVID-19 vaccination prior to participation is strongly recommended. (\*\*) In the event a subject chooses to receive one of the two 2-dose approved or emergency-use-authorized COVID 19 vaccines (Comirnaty® \[Pfizer\], Spikevax™ \[Moderna\]) in the interval between two CRU stays (Cohort 2A/2B or Cohort 3A/3B), flexibility in timing of the second CRU stay should be applied, to allow appropriate receipt of the second vaccine dosage or booster (based on the respective vaccine label) + 14 days, to minimize risk of confounding findings/observations.

Locations (1)

Altasciences Clinical Kansas, Inc.

Overland Park, Kansas, United States

Outcomes

Primary Outcomes

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

Number of participants with at least one TEAE, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Time frame: Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)

Severity of TEAEs After a Single Dose of CD388

Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Time frame: Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)

Secondary Outcomes

Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388

Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)

Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD388

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.

Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388

Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388

Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.

Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD388

Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388

Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.

Mean Apparent Clearance (CL/F) Following a Single Administration of CD388

Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

Median Apparent Clearance (CL/F) Following a Single Administration of CD388

Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.

Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388

Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388

Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.

Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.

Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388

Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388

Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.

Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388

Mean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388

Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).